BIOCHEMISTRY
including biophysical chemistry & molecular biology

RAPID REPORT

pubs.acs.org/biochemistry

Mapping the Ligand-Binding Site on a G Protein-Coupled Receptor (GPCR) Using Genetically Encoded Photocrosslinkers

Amy Grunbeck, Thomas Huber, Pallavi Sachdev, and Thomas P. Sakmar*

Laboratory of Molecular Biology and Biochemistry, The Rockefeller University, New York, New York, United States

Supporting Information

ABSTRACT: We developed a general cell-based photocrosslinking approach to investigate the binding interfaces necessary for the formation of G protein-coupled receptor (GPCR) signaling complexes. The two photoactivatable unnatural amino acids *p*-benzoyl-L-phenylalanine and *p*-azido-L-phenylalanine were incorporated by amber codon suppression technology into CXC chemokine receptor 4 (CXCR4). We then probed the ligand-binding site for the HIV-1 coreceptor blocker, T140, using a fluorescein-labeled T140 analogue. Among eight amino acid positions tested, we found a unique UV-light-dependent crosslink specifically between residue 189 and T140. These results are evaluated with molecular modeling using the crystal structure of CXCR4 bound to CVX15.

G protein-coupled receptors (GPCRs) are dynamic membrane proteins that trigger and regulate cellular signaling pathways. In the classical paradigm of GPCR signaling, an extracellular ligand binds to a specific receptor to activate a heterotrimeric G protein. GPCRs also activate beta-arrestin-dependent kinase pathways.[1] One approach to gain information about GPCR structure and function is to trap a receptor−ligand complex using photoactivatable crosslinkers. Although a number of successful receptor−ligand crosslinking experiments have been reported, the general strategy of synthesizing ligands with photoactivatable groups is conceptually limited and technically challenging.[2,3] Even if crosslinking can be achieved, identifying the site of the crosslink is difficult and sometimes not possible. We have adapted the amber stop codon suppression technology to incorporate site-specifically two unnatural amino acid (UAA) photocrosslinkers, *p*-benzoyl-L-phenylalanine (BzF) and *p*-azido-L-phenylalanine (azF), into GPCRs heterologously expressed in mammalian cells,[4] which provides a means to capture a covalent GPCR-ligand complex. Here, we show how this methodology can be used in cells to probe the binding interface between CXC chemokine receptor 4 (CXCR4) and T140, a CXCR4-specific inhibitor.

CXCR4 mediates directed cell migration in development and during inflammation and cancer metastasis. It is also known to be a coreceptor for cellular HIV-1 entry, and is a[5] target for HIV-1 entry inhibitors.[6] The small molecule CXCR4 antagonist, AMD3100, was the first proof-of-concept HIV-1 entry blocker,[7] which led to the development of CCR5-targeted entry blockers.[8] CXCR4 inhibitors also induce the mobilization of hematopoietic stem cells by disrupting the interaction between CXCR4 and CXCL12, which is necessary for retaining hematopoietic stem cells in the bone marrow.[9−11]

T140, a 14-residue cyclic peptide CXCR4 antagonist, blocks HIV-1 entry.[12] We used the CXCR4−T140 complex to validate a site-specific crosslinking technology for identifying GPCR−ligand binding interfaces. Earlier CXCR4-T140 complex models were developed using mutagenesis and crosslinking techniques. These strategies required digestion of CXCR4 to determine the site in the receptor that was covalently bound to the T140 analogue.[13,14] These experiments were only able to resolve a peptide fragment of CXCR4 that was bound to T140. CXCR4−T140 complex models derived from these studies differ from the crystal structure of CXCR4 bound to CVX15, a 16-residue peptide with high homology to T140.[15] We aimed to develop a site-directed photocrosslinking technology to predict more accurate models of GPCR−ligand complexes even in the absence of available crystal structures. The site-directed crosslinking technology relies on a specific and sensitive detection method to identify both binding partners in the crosslinked complex. We accomplish this by attaching a unique antibody reactive tag on each complex component. CXCR4 contains a C-terminal C9 epitope tag for mAb 1D4, and T140 is labeled with fluorescein (Figure 1a). The fluorescein tag is used for specific detection by immunoblot analysis using an antifluorescein antibody. Fluorescein was directly conjugated to Lys 8 on T140, which does not interfere with binding to CXCR4.[16,17] Thus, fluorescein-T140 (FL-T140) is a suitable ligand to validate the application of the site-directed crosslinking technology.

First, to optimize conditions for crosslinking and detection of the FL-T140/CXCR4 complex, we used a T140 analogue containing fluorescein and BzF at position 10 (FL-T140-BzF). This T140 derivative has been reported to crosslink to CXCR4 and serves as a positive control.[18] We also demonstrated that FL-T140-BzF crosslinks specifically to CXCR4 in cell culture. CXCR4-transfected HEK293T cells were incubated with FL-T140-BzF prior to UV light exposure. Following UV exposure, the cells were solubilized in detergent and CXCR4 was immunopurified from the lysate using sepharose beads conjugated to the 1D4 mAb. An immunoblot of the purified samples showed a UV-treatment-dependent band on the anti-fluorescein blot at the molecular mass of the receptor (Figure S1, Supporting Information). This indicates the existence of a covalent complex between FL-T140-BzF and CXCR4, which was not detected if a 100-fold excess of unlabeled T140 was present. Additionally, no crosslink was detected in untransfected cells or to CCR5,

Received: February 10, 2011
Revised: March 17, 2011
Published: March 18, 2011



Figure 1. Photocrosslinking of CXCR4 UAA mutants to FL-T140. (a) Chemical structure of FL-T140. (b) CXCR4 schematic highlighting sites important for T140 binding (green) as determined by alanine scanning[13] and positions where a UAA was incorporated (orange). (c) Western blot analysis of lysate from HEK293T cells expressing CXCR4 BzF mutants that were exposed to UV light in the presence of FL-T140. CXCR4 189BzF was the only CXCR4 BzF mutant that crosslinked to FL-T140. (d) As a positive control FL-T140-BzF was crosslinked to WT CXCR4. Background crosslinking was not detected between WT CXCR4 and FL-T140. (e) Crosslinking of CXCR4 189BzF to FL-T140 was performed in the absence and presence of a 100-fold excess of unlabeled T140. The band on the antifluorescein blot disappeared in the presence of excess T140. (f) Crosslinking results for CXCR4 189azF to FL-T140. Cross-link was specific for position 189, but background crosslinking, most likely due to exposure to ambient room light, was detected. Background was not detected when BzF was used as the photocrosslinker.

another chemokine receptor with high homology to CXCR4, demonstrating the specificity of T140 for CXCR4.

The CXCR4 schematic shows the sites, which when mutated to an Ala, caused a decrease in T140 inhibition of HIV-1 entry (Figure 1b).[13] Although in principle any amino acid residue can be targeted for amber codon suppression, we chose Phe residues in close proximity to these sites for replacement with BzF or azF in order to make mutations that would be the least likely to perturb the native structure of the receptor. These UAAs were incorporated one-by-one at each position using an engineered BzF or azF amino-acyl tRNA synthetase and suppressor tRNA pair that recognize an amber stop codon (UAG) on the receptor mRNA.[4] Incorporation of BzF at the position of the amber stop codon in CXCR4 was confirmed by immunoblot to detect full-length receptor (Figure S2, Supporting Information).

Introducing UAAs into GPCRs alters the native sequence of the receptor, but the proper folding and function of the receptor can be retained, as has been reported for the incorporation of UAAs into other GPCRs, including rhodopsin and CCR5.[4,19,20] We determined whether incorporation of BzF into CXCR4 affects binding to T140 by examining the crosslinking efficiency of FL-T140-BzF to each of the CXCR4 BzF containing mutants. All of the mutants crosslinked to FL-T140-BzF, indicating that T140 is able to bind to the CXCR4 variants containing BzF (Figure S3, Supporting Information). Each of the CXCR4 BzF mutants were then tested for UV-induced crosslinking to FL-T140.

The results from this series of experiments showed an antifluorescein positive band at the molecular mass of CXCR4 only when BzF was introduced at position 189 (Figure 1c and Figure S4, Supporting Information) or when BzF was at position 10 in FL-T140-BzF (Figure 1d). The same crosslinking experiment was also performed in the presence of 100-fold excess of unlabeled T140. In this case, no band was detected with the antifluorescein antibody, which demonstrates the specificity of the crosslink at position 189 for T140 (Figure 1e). The same results were also seen with azF at the same sites in CXCR4 (Figure S5, Supporting Information), although background crosslinking without UV treatment was significantly higher when using azF as compared to BzF (Figure 1f).

Evaluating our findings in the context of the crystal structure of CXCR4 bound to CVX15 verifies the application of this technology to identify residues in CXCR4 that are within close proximity to the T140 binding site. Assuming that T140 has a similar binding site as CVX15, Phe189 immediately stands out from the other sites as being within crosslinking distance to the ligand (Figure 2a,b). Since the crystal structure is limited to a single static image, we also carried out computational modeling to predict the possible orientations of BzF at each of these sites (Figure 2c). We calculated the distance between the center-of-mass of the reactive carbonyl in BzF to the nearest atom in the CVX15 peptide for each of the possible orientations of BzF at each position. BzF at position 189 was the only site to have a reasonably high probability of being within 2−5 Å from the peptide − all other potential carbonyl-CVX15 atom pairs were greater than 5 Å apart (Figure 2d). This agrees with other reports that the minimum required distance to form a crosslink with a benzophenone group is approximately 3 Å.[21,22]

The main ligand-binding pocket for family A GPCRs is defined as the pocket between the extracellular segments of transmembrane helices III, V, and VI.[23] The CXCR4−CVX15 crystal structure shows that Phe189 is within extracellular loop 2 of CXCR4, which borders the main ligand-binding pocket of CXCR4 and lies within a defined distance from bound T140. In conclusion, our cell-based photocrosslinking technology should prove useful for investigating the structure of GPCR complexes formed within a live cell. In addition, combining a site-directed photocrosslinking technology with available crystal structures could



Figure 2. Molecular modeling of CXCR4 BzF mutants. (a) Crystal structure of CXCR4 bound to CVX15 (cyan) with residues replaced with UAAs highlighted in orange.[15] N-terminus of receptor is highlighted in blue and fades to red at the C-terminus. (b) A 90° rotation of the structure in a, which shows a view from the extracellular side of the receptor. (c) Crystal structure of CXCR4 (gray) bound to CVX15 (stick representation). The side-chain modeling determined 100 potential orientations of BzF at each site examined in the crosslinking experiments, and are highlighted on the structure in stick form. The colored density maps indicate the location of the BzF carbonyl for all potential orientations of BzF at each position. Position 309 is not shown because this view is from the extracellular side of the receptor. (d) A graph of the radial distribution function versus the distance. Distance measurements were made from the carbonyl in BzF to the closest atom in the CVX15 peptide. The graph for position 309 is not visible on this plot because the distance to the ligand is greater than 20 Å. This graph shows that for position 189, CVX15 has the highest probability of being within the reactive radius of 3.1 Å from the carbonyl group in BzF.[21] From this model, the predicted crosslink site on the ligand is Arg11, which is conserved in both CVX15 and T140.

lead to more accurate models of various conformational states of GPCR signaling complexes or "signalosomes."

■ ASSOCIATED CONTENT

Supporting Information. Detailed experimental methods and supplementary figures are available free of charge via the Internet at http://pubs.acs.org.

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: sakmar@rockefeller.edu.

Funding Sources

Support was received from NIH ROI EY12049.

■ ACKNOWLEDGMENT

We thank Manija Kazmi and Shixin Ye for helpful discussions and scientific assistance. We also thank Martin Teintze and Ed Dratz for providing us with FL-T140-BzF and the Proteomic Resource Center at Rockefeller University for the synthesis of the other T140 compounds and Ray Stevens for providing the coordinates for the CXCR4 structure before release. The Tri-Institutional Training Program in Chemical Biology supports A.G.

■ REFERENCES

(1) Shenoy, S. K., and Lefkowitz, R. J. (2005) Angiotensin ii-stimulated signaling through G proteins and β-arrestin. *Sci STKE 2005*, cm14.
(2) Nakayama, T. A., and Khorana, H. G. (1990) *J. Biol. Chem. 265*, 15762–15769.
(3) Chen, Q., Pinon, D. I., Miller, L. J., and Dong, M. Q. (2009) *J. Biol. Chem. 284*, 34135–34144.
(4) Ye, S. X., Kohrer, C., Huber, T., Kazmi, M., Sachdev, P., Yan, E. C. Y., Bhagat, A., RajBhandary, U. L., and Sakmar, T. P. (2008) *J. Biol. Chem. 283*, 1525–1533.
(5) Feng, Y., Broder, C. C., Kennedy, P. E., and Berger, E. A. (1996) *Science 272*, 872–877.
(6) Oberlin, E., Amara, A., Bachelerie, F., Bessia, C., Virelizier, J. L., ArenzanaSeisdedos, F., Schwartz, O., Heard, J. M., ClarkLewis, I., Legler, D. F., Loetscher, M., Baggiolini, M., and Moser, B. (1996) *Nature 382*, 833–835.
(7) Donzella, G. A., Schols, D., Lin, S. W., Este, J. A., Nagashima, K. A., Maddon, P. J., Allaway, G. P., Sakmar, T. P., Henson, G., De Clercq, E., and Moore, J. P. (1998) *Nat. Med. 4*, 72–77.
(8) Seibert, C., and Sakmar, T. P. (2004) *Curr. Pharm. Des. 10*, 2041–2062.
(9) Hattori, K., Heissig, B., Tashiro, K., Honjo, T., Tateno, M., Shieh, J. H., Hackett, N. R., Quitoriano, M. S., Crystal, R. G., Rafii, S., and Moore, M. A. S. (2001) *Blood 97*, 3354–3360.
(10) Liles, W. C., Broxmeyer, H. E., Rodger, E., Wood, B., Hubel, K., Cooper, S., Hangoc, G., Bridger, G. J., Henson, G. W., Calandra, G., and Dale, D. C. (2003) *Blood 102*, 2728–2730.
(11) Tchernychev, B., Ren, Y., Sachdev, P., Janz, J. M., Haggis, L., O'Shea, A., McBride, E., Looby, R., Deng, Q., McMurry, T., Kazmi, M. A., Sakmar, T. P., Hunt, S., III, and Carlson, K. E. (2010) *Proc. Natl. Acad. Sci. U.S.A. 107*, 22255–22259.
(12) Tamamura, H., Hori, A., Kanzaki, N., Hiramatsu, K., Mizumoto, M., Nakashima, H., Yamamoto, N., Otaka, A., and Fujii, N. (2003) *FEBS Lett. 550*, 79–83.
(13) Trent, J. O., Wang, Z. X., Murray, J. L., Shao, W. H., Tamamura, H., Fujii, N., and Peiper, S. C. (2003) *J. Biol. Chem. 278*, 47136–47144.
(14) Boulais, P. E., Dulude, D., Cabana, J., Heveker, N., Escher, E., Lavigne, P., and Leduc, R. (2009) *Biochem. Pharmacol. 78*, 1382–1390.
(15) Wu, B., Chien, E. Y., Mol, C. D., Fenalti, G., Liu, W., Katritch, V., Abagyan, R., Brooun, A., Wells, P., Bi, F. C., Hamel, D. J., Kuhn, P., Handel, T. M., Cherezov, V., and Stevens, R. C. (2010) *Science 330*, 1066–1071.
(16) Oishi, S., Masuda, R., Evans, B., Ueda, S., Goto, Y., Ohno, H., Hirasawa, A., Tsujimoto, G., Wang, Z. X., Peiper, S. C., Naito, T., Kodama, E., Matsuoka, M., and Fujii, N. (2008) *ChemBioChem 9*, 1154–1158.
(17) Nomura, W., Tanabe, Y., Tsutsumi, H., Tanaka, T., Ohba, K., Yamamoto, N., and Tamamura, H. (2008) *Bioconjugate Chem. 19*, 1917–1920.
(18) Wilkinson, R. A., Pincus, S. H., Shepard, J. B., Walton, S. K., Bergin, E. P., Labib, M., and Teintze, M. (2011) *Antimicrob. Agents Chemother. 55*, 255–263.
(19) Ye, S. X., Huber, T., Vogel, R., and Sakmar, T. P. (2009) *Nat. Chem. Biol. 5*, 397–399.
(20) Ye, S. X., Zaitseva, E., Caltabiano, G., Schertler, G. F. X., Sakmar, T. P., Deupi, X., and Vogel, R. (2010) *Nature 464*, 1386–1389.
(21) Dorman, G., and Prestwich, G. D. (1994) *Biochemistry 33*, 5661–5673.
(22) Sato, S., Mimasu, S., Sato, A., Hino, N., Sakamoto, K., Umehara, T., and Yokoyama, S. (2011) *Biochemistry 50*, 250–257.
(23) Rosenkilde, M. M., Benned-Jensen, T., Frimurer, T. M., and Schwartz, T. W. (2010) *Trends Pharmacol. Sci. 31*, 567–574.